Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Male
Adult
Medical Sciences
Bioinformatics
610
Transplantation, Autologous
Article
Biomedical Informatics
0302 clinical medicine
Medical Specialties
Medicine and Health Sciences
Humans
RC254-282
Aged
Retrospective Studies
Transplantation
Remission Induction
Hematopoietic Stem Cell Transplantation
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Middle Aged
Treatment Outcome
Oncology
Female
Multiple Myeloma
Autologous
DOI:
10.1038/s41408-024-01062-2
Publication Date:
2024-05-17T07:02:53Z
AUTHORS (22)
ABSTRACT
AbstractAutologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small proportion achieve a durable response. In this retrospective study we included 1576 patients, 244 (15%) of whom were long-term responders (LTR), defined as having a progression-free survival (PFS) of ≥8 years after transplant. Patients in the LTR group were younger than the non-LTR group (median age 58.4 vs. 59.5 years; p = 0.012), less likely to have high-risk cytogenetics (4% vs. 14%; p < 0.001), more often had <50% bone marrow plasma cells (67% vs. 58%; p = 0.018) and R-ISS stage I disease (43% vs. 34%). More patients in the LTR group received post-transplant maintenance (63% vs. 52%; p = 0.002). Patients in the LTR group had higher rates of complete response (CR) at day100 (41% vs. 27%; p < 0.001) and at best post-transplant response (70% vs. 37%; p < 0.001), compared to the non-LTR group. Patients in the LTR groups had a median PFS of 169.3 months and the median overall survival (OS) had not been reached. The leading cause of death in the LTR was disease progression. In conclusion, 15% of patients in the cohort were LTR after upfront autoHCT, with distinct characteristics and a median PFS of more than 14 years.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (26)
CITATIONS (7)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....